Chromothripsis is more commonly detected in AML patients with TP53 mutations (8/17, 47.1%) than in AML patients with the TP53 wild type (1/91, 1.1%), and it is more commonly detected in cases of complex karyotype AML (22/56, 39.3%) than in noncomplex karyotype AML cases (0/255, 0%) [13]. This evidence concerns the gene TP53 and acute myeloid leukemia.